P olygenic risk scores (PGS) represent a powerful tool in the study of complex genetic traits and provide the unique opportunity for direct application of results from genomewide association studies (GWAS) to clinical populations. The conceptual basis for PGS is that for many complex genetic traits, there exist multiple variants of modest effect size that are responsible for the phenotype. In contrast, for single-gene or Mendelian traits, only a single gene accounts for most of the effect. PGS are being increasingly applied to a range of traits for which GWAS have been completed. [1] [2] [3] [4] [5] [6] However, like any predictive tool, PGS must be validated in separate populations from those in which they were derived, which is not always feasible given the large populations needed for discovery.
In addition to external validation, an aspect requiring further exploration in application of PGS is the number of variants to include. Many applications of PGS have used a significance cutoff for inclusion of variants based on the level of genome-wide significance (P<5×10 −8 ) obtained from the original GWAS. However, investigators have noted that for certain traits, such as schizophrenia, 7 inclusion of a greater number of variants in a PGS through relaxation of the significance threshold from the original GWAS has been found to increase the proportion of heritability explained, [7] [8] [9] at least as applied to binary disease states. It is unknown whether this same principle would apply to other conditions or to the proportion of variation explained for a continuous quantitative measure, such as the QT interval. As the impact of including greater or fewer numbers of variants in the PGS seems to be condition-specific, 10 it is necessary to examine its impact in each trait individually. In this study, we examine a PGS applied to the resting QT interval.
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Prolongation of the QT interval is associated with an increased risk of sudden cardiac death 11, 12 and is a major side effect of many cardiac and noncardiac medications. 13 Prolongation of the QT interval is the number one reason for new-drug rejection by the Food and Drug Administration, and Background-Polygenic risk scores (PGS) enable rapid estimation of genome-wide susceptibility for traits, which may be useful in clinical settings, such as prediction of QT interval. In this study, we sought to validate PGS for QT interval in 2 real-world cohorts of European ancestry (EA) and African ancestry (AA). Methods and Results-Two thousand nine hundred and fifteen participants of EA and 366 of AA in the MGH CAMP study (Cardiology and Metabolic Patient) were genotyped on a genome-wide array and imputed to the 1000 Genomes reference panel. An additional 820 EA and 57 AA participants in the Partners Biobank were genotyped and used for validation. PGS were created for each individual using effect estimates from association tests with QT interval obtained from prior genome-wide association studies, with variants selected based from multiple significance thresholds in the original study.
In regression models, clinical variables explained ≈9% to 10% of total variation in resting QTc in EA individuals and ≈12% to 18% in AA individuals. The PGS significantly increased variation explained at most significance thresholds (P<0.001), with a trend toward increased variation explained at more stringent P value cut points in the CAMP EA cohort (P<0.05). In AA individuals, PGS provided no improvement in variation explained at any significance threshold.
Conclusions-For individuals of European descent, PGS provided a significant increase in variation in QT interval
explained compared with a model with only nongenetic factors at nearly every significance level. There was no apparent benefit gained by relaxing the significance threshold from conventional genome-wide significance (P<5×10 Polygenic Scores for QT Interval prolongation of as little as 10 ms has caused the removal of drugs from the market. 14 The QT interval is heritable, with estimates that around 30% to 40% of the variance in the QT interval can be explained by additive genetic factors. [15] [16] [17] Several increasingly large GWAS of QT interval have been reported. The largest GWAS in individuals of European descent was reported by the QT Interval-International GWAS Consortium, which included results on over 70 K individuals. 18 In individuals of African descent, the CARe-COGENT consortium (CandidateGene Association Resource-Continental Origins and Genetic Epidemiology Network) has reported the largest study to date, comprising 12 K individuals. 19 From these GWAS, we obtained effect estimates and significance levels for thousands of variants associated with the QT interval, which we apply in this study.
In the current report, we examined PGS of QT interval in individuals of African and European descent in 2 separate real-world cohorts, ascertained under separate conditions, before and after adjustment for clinical factors.
Methods

PGS Derivation in Individuals of European Descent
The QT Interval-International GWAS Consortium performed a metaanalysis of GWAS in 76 061 individuals of self-reported European ancestry (EA) with targeted genotyping in ≤33 316 additional individuals and is described in detail elsewhere. 18 These values were then summated across all variants used to get a PGS estimate for the QT interval for each individual at each significance threshold (negative log 10 P value of 2-12).
PGS Derivation in African Americans
The CARe-COGENT GWAS included 10 cohorts of self-reported black or African American individuals with genome-wide SNP data as part of the Continental Origins and Genetic Epidemiology Network, the Candidate-Gene Association Resource consortium, and the Women's Health Initiative SNP Health Association Resource, in which 13 105 individuals had genotypes imputed to 2.8 million variants and examined for association with QT interval. 22 This study found no difference in QT interval duration with global genetic indices of African ancestry (AA), but did identify 2 SNPs at genomewide significance (P<2.5×10 -8 ). 22 We obtained 3 144 424 SNPs with effect size and significance from this study and pruned them for LD based on an r 2 of 0.05 with the lead SNP, at a distance of 500 kb, with HapMap2 YRI (release No. 23a, March 2008, on NCBI B36 assembly) as the reference genome. After pruning, we obtained 35 966 variants (lead SNPs for each clump), of which 10 153 SNPs were associated with resting QT interval at P≤1×10 -2 . These SNPs were then divided according to -log 10 P from 2 to 12 (Table 1) , and PGS were calculated for each subject at each significance threshold as described earlier for EA individuals. Table IB in the Data Supplement displays the SNPs with negative log P value of ≥6, with estimates from the original GWAS.
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PGS Test Cohorts
Cardiovascular and Metabolic Patient
The CAMP cohort is composed of 3756 individuals who underwent assessment of demographic data, past medical history, including medications, and a single resting ECG measurement. Of these initial individuals, 3731 were genotyped and imputed to the 1000 Genomes reference panel. After exclusions (QRS>120 ms, heart rate >120 bpm), a final study sample of 3281 individuals was obtained ( Table 2) .
Partners HealthCare Biobank
Samples, genomic data, and health information were obtained from the Partners HealthCare Biobank (PHB), a biorepository of consented patient data and samples at Partners HealthCare (parent organization of Massachusetts General Hospital and Brigham and Women's Hospital). Using the Partners Research Patient Data Registry query tool, we obtained demographic data, past medical history, and medication history on 4930 genotyped individuals, which were then merged with the ECG measurements, resulting in 877 individuals who were of either EA or AA (Table 2 ) and were used in our analyses. For individuals with >1 ECG available, the tracing containing the median QTc was used for analysis. All study subjects provided written informed consent, and all study protocols were approved by local institutional review boards.
Genetic Imputation
The CAMP cohort was genotyped on Illumina Infinium HumanCoreExome-24 BeadChips and imputed to 1000 Genomes Reference Panel (Phase1, v3) using Impute2 (version 2.3.1). PHB was genotyped on Illumina arrays and imputed to 1000 Genomes using Mach 23 (Center for Statistical Genetics, University of Michigan, MI, http://genome.sph.umich.edu/wiki/Mach). Genetic dosage from imputation was used in all analyses.
Statistical Analysis
Pruning for LD was performed using the clump function of PLINK v1.90b3.36 (accessed March 31, 2016), with minimum r 2 =0.05 for each haplotype block, distance of 500 kb, significance threshold for index SNPs of 0.05, and secondary significance of clumped SNPs of 0.05. PGS were calculated for each of the -log 10 P cut points in individuals of self-described EA and AA based on effect estimates obtained in the QT Interval-International GWAS Consortium and CARe-COGENT GWAS, respectively, using the score function in PLINK.
The heart rate-corrected QT interval (Fridericia) was used as the quantitative outcome for all analyses, with focus on the amount of variation in QTc explained by clinical and genetic factors. During sensitivity analysis, the RR interval was also found to be significantly associated with QTc (Fridericia) in at least one cohort, and so it was included as an additional covariable in all models. The QT genotype score was calculated for each individual using SNPs that were significant from the original GWAS at a −log 10 P value of 2 through 12. Three separate models were fit using multivariable linear regression: (1) a baseline model examining the association of heart rate-corrected QT interval with QT genotype score; (2) a minimally adjusted model, including QT genotype score, as well as age and sex; and (3) a fully adjusted model, including QT genotype score, age, sex, antiarrhythmic and cardiac medication use, and past medical history. Variation in QTc interval was calculated as the R 2 for the linear regression model. Trends were examined using Pearson correlation. Statistical analysis was performed using R (Version 3.1.1) and Stata IC (Version 13, StataCorp LP, College Station, TX).
Results
Clinical and demographic data are presented in Table 2 . Both cohorts were composed of predominantly individuals of EA, who were older on average than those of AA. Individuals from the Partners Biobank, who underwent ECG only as part of clinical care, were more likely to be on cardiac medications, including β-blockers, calcium-channel blockers, and antiarrhythmic agents. These individuals also had a marginally longer baseline QTc than individuals from the CAMP study. The QTc was also longer in individuals of EA than AA, although the difference did not reach statistical significance in the Partners Biobank cohort (P=0.42), and the difference was not significant after adjustment for age, sex, and hypertension (P=0.02 before adjustment and P=0.87 after adjustment) in the CAMP cohort, all of which were unequally distributed across race ( Table 2 ). The overall distribution of variation in QTc was not appreciably different between races in either cohort ( Figure IA and IB in the Data Supplement).
The distribution of number of variants included in the QT PGS at different significance thresholds was highly different between individuals of African and European descent, both before and after pruning for LD (Table 1) . There was a greater degree of pruning in EA than AA, indicating a higher Parentheses indicate either standard deviation or percentage of total population as appropriate. AF indicates atrial fibrillation; BMI, body mass index; Class 1A AAD, Vaughn-Williams class 1A antiarrhythmic drug use; Class 3 AAD, Vaughn-Williams class 3 antiarrhythmic drug use; CVA, cerebrovascular accident (stroke); HF, heart failure; HTN, hypertension; MI, myocardial infarction; and QTc, corrected QT interval (Fridericia). Polygenic Scores for QT Interval degree of LD. Both PGS had substantially more variants included as the significance threshold for use in the genotype score was relaxed, although the discrepancy was greater in the AA CARe-COGENT (African) GWAS, where a decrease in the -log 10 P value for inclusion from 4 to 3 to 2 resulted in nearly an order of magnitude increase in the number of variants included. This pattern was also reflected in the variance in the QT PGS in each population ( Figures 1A and 1B) . Of note, at no threshold were there any index SNPs in common between the European and African QT genotype score (it is likely that there were multiple highly correlated nonindex SNPs that were in common, although exploration of this topic was beyond the scope of our study).
For individuals with EA, the QT PGS explained a significant amount of variation in resting QTc at nearly all significance thresholds, with the only exception being at a P value threshold of 10 -2 in the PHB cohort (Figure 2A ). At the most predictive level (negative log P value =7), the average difference in QTc between the highest and lower quintiles was 8.5 ms (95% confidence interval, 6.3-10.7 ms; N=583 per quintile) in CAMP ( Figure 3A ) and 15.3 ms (95% confidence interval, 10.7-19.9 ms; N=164 per quintile) in the PHB cohort ( Figure 3B ). For individuals of AA, genetic risk score had no significant improvement above clinical factors at any significance threshold ( Figure 2B ). Inclusion of clinical factors increased the overall variation in QTc interval explained in all models but had little effect on the pattern seen for any particular cohort or race (Figures II and III in the Data Supplement). Despite the increase in genetic variance with less stringent significance threshold, there was no significant increase in the additive heritability for either EA or AA, with the PHB European cohort actually demonstrating a significant trend toward decreased variation in QTc explained (ie, lower R 2 ), with inclusion of more variants (P<0.05). Of note, the PGS created from the European population did not explain a significant amount of variation in QTc in the African populations in either cohort.
Discussion
In this investigation of 2 real-world populations, we found that a PGS developed from prior GWAS of QT interval explained a significant amount of variation in QTc interval for individuals of EA, but not AA. Using more permissive levels of significance for inclusion of variants (lower P value cut point from the original GWAS), we were unable to improve the ability of the PGS to explain QTc, and in Europeans, it seems that lowering the threshold for inclusion below that used ) seemed to trend toward only increasing the amount of noise. These findings are important because they provide real-world validation to prior studies on the use of PGS in predicting QTc in European populations 12 and suggest that larger investigations may be needed in individuals of AA to identify more reliable point estimates of effect and remove noisy variants.
This study highlights an important limitation of the application of PGS to QT interval, and perhaps to many other traits and disease states, which is that PGS are only as useful as the power of the GWAS underlying its estimates. This limitation was most apparent in the contrast between individuals of AA and EA, in which a large GWAS of over 70 000 individuals (QT Interval-International GWAS Consortium) was performed to identify the variants for the European score, while a smaller GWAS of 13 000 individuals (CARe-COGENT) was used to identify variants in African individuals. Given the lower levels of LD present in African populations, 24 this difference in size of GWAS is practically the opposite of what would be needed to obtain sufficient power to identify associated variants at genome-wide levels of significance. In addition to limitations in identification of variants of association, the contrast in LD also limits the ability to impute genotypes in the population to which the PGS is being applied, 25 which would also explain why the PGS failed to explain variation in QT interval in either AA population we studied. Clearly, larger GWAS in African individuals will be needed to examine the role of PGS as an independent predictor of QT interval.
Another important finding from our study was that, in Europeans, a small number of variants seem to explain most of the heritability of resting QT interval. This finding is in contrast to studies of other phenotypes, such as breast cancer, where simulation studies have suggested that PGS composed of a larger number of rare variants of moderate effect may explain the greatest amount of heritability. 10 An obvious difference from prior study was that the QT interval is a continuous quantitative biological trait, while breast cancer is a binary disease state. The implication of this explanation is that fewer genes may play a role in the determination of the resting QT interval, while perhaps a larger number are capable of causing or contributing to the risk of breast cancer. However, one cannot rule out that the observed difference could simply be a statistical limitation because of comparing regression of a transformed outcome (ie, logistic regression used for binary outcomes) with linear regression of a continuous outcome. Further research using similar approaches to ours will be needed to examine whether this effect was reflective of the genetic architecture of the QT interval, is a characteristic of all quantitative traits, or is simply a statistical aberration.
Prolonged resting QT interval is associated with increased risk of sudden cardiac death, 26 and identification of genetic markers of PGS could be useful as a surrogate predictor, particularly in populations already genotyped, in which obtaining an ECG would be time-consuming. As sudden cardiac death itself is a rare condition, larger studies will be needed to determine whether a PGS for QT interval is also associated with the risk of sudden death. Additionally, based on the concept of repolarization reserve, 14, 27, 28 it is feasible that individuals with a genetic predisposition to QT prolongation would be expected to have an exaggerated QT prolongation with medications or other environmental factors (heart failure, hypokalemia), an area of active investigation. The granularity of data required to examine this question was not available in our study, although we have plans to examine the interaction of medications and other real world factors with genetic effects on the QT interval. Nonetheless, our finding that the PGS explains nearly (CAMP) or greater than (PHB) the increase in QTc that has resulted in certain medications being removed from the market 14 populations. Individuals in the CAMP cohort were entirely outpatients and underwent an ECG as an elective procedure, while subjects in the PHB population were more likely to have undergone an ECG to evaluate for cardiac disease. This difference was apparent in the increased number of subjects with a history of cardiac disease or taking cardiac medications in the PHB population than in the CAMP cohort. Although we were underpowered to specifically examine the impact of this difference, limited studies of healthy subjects off medications and without cardiac disease suggest that it had little impact on the overall results (data not shown). Further investigations, which we have planned, will examine the interaction of cardiac disease and medications with genetic predictors of QT interval and will provide greater insight. Another potential limitation of this study was the impact of pruning for LD, which as highlighted earlier was a key limitation in application of PGS to African populations. It is entirely possible that variants in LD with the lead variant may have had additional effect on QT interval but may have been excluded. This limitation may explain the relatively smaller amount of heritability of the QT interval explained in this study relative to others. 12, 29 Future investigations, including those based on GWAS with rare variants in addition to common ones, will likely be needed to examine the impact of patterns of LD on the QT interval. It is also likely that the differential effects of LD between African and European populations will be overcome with future, larger GWAS for QT interval in African populations.
In summary, in this investigation we found that a PGS created from prior GWAS of resting QT interval explained a significant amount of variation in QTc interval at nearly all significance levels in individuals of European descent but not African descent. Despite increasing the total genetic variance through inclusion of variants at less significance thresholds, there was no increase in the variation in QTc interval explained; in contrast, we found a trend toward less variation explained with less stringent inclusion criteria. Further studies will be needed to expand these findings to better understand the genetic architecture of cardiac repolarization.
